Olatoyosi Odenike to Risk Assessment
This is a "connection" page, showing publications Olatoyosi Odenike has written about Risk Assessment.
Connection Strength
0.077
-
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy. Blood Adv. 2024 Oct 22; 8(20):5297-5305.
Score: 0.036
-
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Rev. 2023 11; 62:101128.
Score: 0.033
-
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22.
Score: 0.009